Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Type 2 DiabetesHypogonadism
Interventions
DRUG

Androgel (testosterone gel)

Trial Locations (70)

Unknown

Site 58, Birmingham

Site 67, Calera

Site 54, Mobile

Site 16, Phoenix

Site 35, Anaheim

Site 23, Concord

Site 55, La Jolla

Site 8, Los Gatos

Site 12, Mission Viejo

Site 1, Torrance

Site 25, Glastonbury

Site 13, Fort Lauderdale

Site 43, Jacksonville

Site 33, Ocala

Site 27, Tampa

Site 21, West Palm Beach

Site 7, Atlanta

Site 26, Columbus

Site 29, Boise

Site 45, Idaho Falls

Site 51, Chicago

Site 32, Des Moines

Site 5, Baton Rouge

Site 70, Baltimore

Site 9, Springfield

Site 48, Watertown

Site 19, Detroit

Site 61, Livonia

Site 40, Tupelo

Site 65, Chesterfield

Site 15, Kansas City

Site 41, Omaha

Site 34, Las Vegas

Site 24, Jersey City

Site 49, Buffalo

Site 71, New York

Site 44, Fayetteville

Site 28, Morehead City

Site 60, Morehead City

Site 31, Portland

Site 3, Portland

Site 68, Altoona

Site 4, Bala-Cynwyd

Site 64, Carlisle

Site 38, Lansdale

Site 46, Shippensburg

Site 14, Greer

Site 20, Arlington

Site 11, Dallas

Site 10, Houston

Site 18, Houston

Site 2, Houston

Site 36, Houston

Site 39, Houston

Site 42, Houston

Site 47, Houston

Site 53, Houston

Site 62, Houston

Site 63, Houston

Site 69, Houston

Site 6, Humble

Site 30, La Porte

Site 66, Midland

Site 37, San Antonio

Site 56, Sugarland

Site 57, Sugarland

Site 52, Ogden

Site 17, Salt Lake City

Site 22, Salem

Site 50, Seattle

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00141492 - Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes | Biotech Hunter | Biotech Hunter